CP
CPIX.US Cumberland Pharmaceuticals Inc
- Market cap
- USD 88.2M
- P/E
- -
- P/B
- 1.36x
- ROE
- 129.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CPIX.US undervalued?
Graham numberThe Graham number of Cumberland Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cumberland Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Cumberland Pharmaceuticals Inc yet.
Cumberland Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients rece…
Full company profileCumberland Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cumberland Pharmaceuticals Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 33.0M | 41.2M | 40.7M | 34.4M | 37.4M | 36.0M | 42.0M | 39.6M | 37.9M | 44.5M | 15.3M |
| Gross Profit | 27.1M | 33.8M | 33.4M | 27.0M | 28.8M | 27.2M | 32.9M | 33.5M | 31.3M | 37.9M | 11.2M |
| Operating Income | -1.43M | -4.08M | -7.39M | -9.29M | -6.38M | -7.68M | -5.70M | -9.55M | -6.43M | -2.79M | -11.0M |
| EBITDA | 1.17M | -1.13M | -8.19M | -4.64M | -1.56M | -858K | 333K | 153K | 182K | 2.96M | -7.64M |
| Net Income | -945K | -7.98M | -6.96M | -3.54M | -3.34M | -3.51M | -5.57M | -6.28M | -6.48M | -2.84M | 94.0M |
| EPS | -0.06 | -0.50 | -0.45 | -0.23 | -0.22 | -0.24 | -0.38 | -0.44 | -0.46 | -0.19 | 6.13 |
| Balance Sheet | |||||||||||
| Total Assets | 93.4M | 93.2M | 113M | 105M | 96.5M | 84.5M | 92.9M | 81.8M | 75.6M | 76.8M | 114M |
| Total Liabilities | 20.3M | 29.3M | 57.1M | 53.5M | 49.6M | 41.9M | 57.0M | 52.5M | 53.0M | 52.3M | 41.6M |
| Shareholders' Equity | 73.1M | 63.9M | 55.8M | 51.1M | 47.0M | 42.8M | 36.3M | 29.6M | 22.9M | 24.9M | 72.5M |
| Cash & Short-term Investments | 50.1M | 50.1M | 36.2M | 28.2M | 24.8M | 27.0M | 19.8M | 18.3M | 18.0M | 11.4M | 80.6M |
| Total Debt | 4.10M | 9.80M | 20.0M | 21.5M | 19.3M | 16.1M | 21.0M | 18.4M | 20.6M | 10.2M | 4.60M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 569K | -558K | 3.11M | 3.06M | 5.42M | 6.34M | 8.45M | 6.09M | -612K | 4.93M | -1.26M |
| Capital Expenditure | 2.13M | 1.49M | 4.28M | 246K | 2.11M | 354K | 2.07M | 453K | 180K | 97.9K | 64.1K |
| Free Cash Flow | -1.56M | -2.05M | -1.16M | 2.81M | 3.30M | 5.99M | 6.38M | 5.64M | -792K | 4.83M | -1.33M |
| Ratios | |||||||||||
| ROE | -1.3% | -12.5% | -12.5% | -6.9% | -7.1% | -8.2% | -15.4% | -21.2% | -28.4% | -11.4% | 129.7% |
| ROA | -1.0% | -8.6% | -6.2% | -3.4% | -3.5% | -4.2% | -6.0% | -7.7% | -8.6% | -3.7% | 82.6% |
| Net Profit Margin | -2.9% | -19.4% | -17.1% | -10.3% | -8.9% | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% | 615.7% |
| Debt to Equity | 0.06x | 0.15x | 0.36x | 0.42x | 0.41x | 0.38x | 0.58x | 0.62x | 0.90x | 0.41x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cumberland Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 135K | 0.01 | - |
| 2019 | - | - | - |
| 2018 | USD 56.0M | 3.59 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jul 6, 2007.
Who owns Cumberland Pharmaceuticals Inc
- Insiders 41.57%
- Institutions 21.16%
- Public & others 37.27%
- Shares outstanding 15.0M
- Free float 8.75M
Top funds holding CPIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 275K | 1.83% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 50.0K | 0.33% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 47.8K | 0.32% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 42.6K | 0.28% | -7.35% | Sep 2026 |
| iShares Micro-Cap ETF | 26.2K | 0.18% | 0.00% | Oct 2026 |
| Nationwide Bailard Sm Cp Val M | 24.6K | 0.16% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 24.3K | 0.16% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 17.9K | 0.12% | 0.00% | Sep 2026 |
| DFA U.S. Targeted Value I | 14.0K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 13.5K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 11.3K | 0.08% | 0.00% | Aug 2026 |
| DFA U.S. Small Cap I | 6.36K | 0.04% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 4.95K | 0.03% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 2 Instl | 4.93K | 0.03% | 0.00% | Sep 2026 |
| DFA US Sustainability Core 1 | 4.56K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 4.50K | 0.03% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 3.76K | 0.03% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 2 ETF | 3.70K | 0.02% | 0.00% | Oct 2026 |
| DFA US Vector Equity Class F | 3.67K | 0.02% | 0.00% | Aug 2026 |
| JNL/DFA US Small Cap A | 2.80K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding CPIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Ikarian Capital, LLC | 503K | 3.36% | -9.04% | Jun 2026 |
| Renaissance Technologies Corp | 478K | 3.19% | +1.61% | Jun 2026 |
| Vanguard Capital Management, LLC | 379K | 2.53% | +4.90% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 184K | 1.23% | -21.13% | Sep 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 113K | 0.75% | -11.86% | Jun 2026 |
| Geode Capital Management, LLC | 108K | 0.72% | -5.14% | Jun 2026 |
| Perceptive Advisors LLC | 97.0K | 0.65% | -50.77% | Jun 2026 |
| Citadel Advisors Llc | 73.4K | 0.49% | +340.97% | Jun 2026 |
| BlackRock Inc | 63.5K | 0.42% | +11.70% | Jun 2026 |
| Bank of New York Mellon Corp | 58.5K | 0.39% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 56.7K | 0.38% | +288.45% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 54.9K | 0.37% | +20.35% | Jun 2026 |
| State Street Corp | 39.5K | 0.26% | 0.00% | Jun 2026 |
| UBS Group AG | 26.3K | 0.18% | +407.59% | Jun 2026 |
| Bridgeway Capital Management, LLC | 26.2K | 0.17% | -83.97% | Jun 2026 |
| Bailard Inc | 24.6K | 0.16% | 0.00% | Sep 2026 |
| Quadrature Capital Limited | 24.0K | 0.16% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 24.0K | 0.16% | +116.34% | Jun 2026 |
| Northern Trust Corp | 22.0K | 0.15% | +11.99% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 20.3K | 0.14% | 0.00% | Jun 2026 |
Cumberland Pharmaceuticals Inc company profile
- Company name
- Cumberland Pharmaceuticals Inc
- Ticker
- CPIX.US
- Exchange
- USA Stocks
- Listed since
- Aug 11, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 93
- Fiscal year end
- December
- Address
- 1600 West End Avenue, Nashville, TN, United States, 37203
- Phone
- 615 255 0068
- Website
- cumberlandpharma.com
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Cumberland Pharmaceuticals Inc management
4- Mr. A. J. Kazimi MBAFounder, Chairman, President & CEO · born 1958
- Mr. John Michael Hamm C.M.A.Vice President Accounting & Finance and CFO · born 1956
- Mr. Todd M. AnthonySenior VP of Operations & Chief Compliance Officer · born 1961
- Mr. Adam S. MostafaManaging Director of Banking & Investor Relations · born 1980